For Performance Year 2026, CMS ties GUIDE dementia-care payment to five quality and cost measures for the first time. For family caregivers, that shift makes care plans, caregiver support, medication safety, and respite more central to routine dementia care.
GUIDE is a voluntary nationwide CMS test for dementia care. It began July 1, 2024 and runs through June 30, 2032, CMS explains on its GUIDE Model page. Performance Year 2026 runs July 1, 2026 to June 30, 2027, Elli Cares reports in its summary of CMS Performance Measurement Manual v3.0.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Register through CMS’s official page — Use this page to review requirements and register directly.
- Read the official guidance from CMS — Use this primary source to verify the official guidance.
Table of Contents
- What CMS scores in 2026
- How daily life and caregiver strain are scored
- What the drug-safety check changes
- What care and respite you can plan for
What CMS scores in 2026
CMS's May 18, 2026 manual defines five measures in four domains. They are high-risk medications, patient quality of life, caregiver impact, total per-capita cost, and long-term nursing-home stays.
The mix reflects GUIDE's aims of better daily life, less caregiver strain, and staying home. For planning, it means clinics have reason to track daily function, caregiver load, drugs, costs, and nursing-home moves together.
How daily life and caregiver strain are scored
Patient quality of life uses two PROMIS-10 surveys about 12 months apart. It counts patients whose physical- and mental-health scores stay the same or improve, adjusted for baseline score, dementia severity, caregiver presence, and residence type. Caregiver impact uses the 22-item Zarit Burden Interview. With the quality-of-life measure, each carries up to 3% upside in 2026, Elli Cares explains in its guide to PROMIS-10 and Zarit.
PROMIS-10 is a general health questionnaire, not a dementia-specific test. It uses a U.S. average T-score of 50. Stable scores can reflect test limits rather than real daily change, Elli Cares notes.
What the drug-safety check changes
The high-risk-drug measure is now claims-based and needs no clinic reporting, Elli Cares reports summarizing the CMS manual. It follows NCQA's DAE list for patients 67 and older with two or more fills. It adds antipsychotics and benzodiazepines as potentially inappropriate in dementia.
In the same 2026 formula, it is worth -0.5% to +1%. For families, the practical step is a full medication review at each care-plan visit. Bring all prescriptions, sleep aids, and anxiety drugs to that review.
What care and respite you can plan for
GUIDE requires an initial comprehensive assessment with a home visit, a written person-centered care plan, 24/7 access to a team member or helpline, and caregiver education. Eligible families can receive up to $2,625 in provider-billed respite for PY 2026, CMS states in its MLN Fact Sheet.
CMS limits GUIDE enrollment and respite in its FAQs to: Bring drug lists, daily routines, safety concerns, and caregiver schedules to the first visit. That detail makes the written plan and respite choice fit real home life.
- Original Medicare Parts A and B with clinician-confirmed dementia
- No Medicare Advantage, PACE, hospice, or long-term nursing-home care
- For respite: moderate-to-severe dementia plus an unpaid primary caregiver
You Might Also Like
- Public Input Shaping the 2026-2035 National Alzheimer’s Plan: Care-Planning Implications for Rural Dementia Families
- Social Connection in the 2026 WHO Dementia Guideline: What the Evidence Supports and Does Not Promise for Adults Over 65
- Smoking and Alcohol in the 2026 WHO Dementia Guideline: What the Evidence Supports and Does Not Promise for Adults Over 65
